The carcinogenic risk of high dose total body irradiation in non-human primates

Broerse, J.J.; Bartstra, R. W.; Bekkum, D. W. van; Hage, M. H. van der; Zürcher, C.; Zwieten, Matthew J. van; Hollander, C.F.

doi:10.1016/s0167-8140(00)00147-x

Cited by 17 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The high incidence of malignant glomus tumors is of note, because this is an unusual neoplasm in man. The 4 malignant glomus tumors were localized in the sacral, scrotal, mandibular, and elbow areas (6). The leiomyomas were all found in the uterus.…”

Section: Resultsmentioning

confidence: 99%

“…Tissues were fixed in 10% neutral-buffered formalin and processed using standard histological techniques for light microscopy; electron microscopy was performed when indicated. The data on carcinogenic risk were published earlier (6), however, at that time, data on benign tumors were not complete as well as those regarding nontumorigenic lesions. Considering the relatively small number of animals per group, the calculations have been combined for both sexes.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Tumorigenesis in High-Dose Total Body Irradiated Rhesus Monkeys—A Life Span Study

2003

Self Cite

View full text Add to dashboard Cite

In the early sixties, studies have been performed at the TNO-Institutes for Health Research on acute effects of high dose total body irradiation (TBI) with X-rays and fission neutrons in Rhesus monkeys and the protective effect of autologous bone marrow transplantation (BMT). The surviving animals of this study were kept to investigate late radiation effects, ie, tumorigenesis. TBI in combination with chemotherapy, followed by rescue with BMT is increasingly used for the treatment of hematological malignancies and refractory autoimmune disease. The risk of radiation carcinogenesis after this treatment is of growing concern in man. Studies on tumor induction in nonhuman primates are of relevance in this context since the response of this species to radiation does not differ much from that in man. The group of long-term surviving monkeys comprised nine neutron irradiated animals (average total body dose 3.4 Gy, range 2.3-4.4 Gy) and 20 X-irradiated monkeys (average total body dose 7.1 Gy, range 2.8-8.6 Gy). A number of 21 age-matched nonirradiated Rhesus monkeys served as a control-group. All animals were regularly screened for the occurrence of tumors.Complete necropsies were performed after natural death or euthanasia. At postirradiation intervals of 4-21 years an appreciable number of malignant tumors was observed. In the neutron irradiated group eight out of nine animals died with 1 or more malignant tumors. In the X-irradiated group this fraction was 10 out of 20. The tumors in the control group, in seven out of 21 animals, appeared at much older age compared with those in the irradiated cohorts. The histogenesis of the malignant tumors was diverse, as was the case for benign tumors. The observed shortening of latency periods and life span, as well as, the increase of mean number of tumors per tumor bearing animal for benign neoplasms parallels the trend observed for malignant tumors. The results of this study were compared to other radiation late effects after TBI followed by different BMT treatment modalities in Rhesus monkeys. The observation that the carcinogenic risk of TBI in the Rhesus monkeys is similar to that derived from the studies of the Japanese atomic bomb survivors and the increase of the risk by a factor of 8 emphasizes the need for regular screening for secondary radiation-induced tumors in long-term surviving patients after TBI followed by BMT.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Tumorigenesis in High-Dose Total Body Irradiated Rhesus Monkeys—A Life Span Study

2003

Self Cite

View full text Add to dashboard Cite

show abstract

“…Regardless of the final diagnosis, reports of tumors with plasma cell differentiation in non‐human primates are exceedingly rare [2, 10, 17, 21]. Additionally, the cardiac involvement in this case is unique when compared to human tumors and is likely indicative of the aggressive nature of this tumor.…”

Section: Case Reportmentioning

confidence: 93%

“…1 Values are shown as mean (SD). 2 Time of peak B cells varied, but was between 49 and 58 weeks post-inoculation. 3 Time at return to baseline = 79 weeks.…”

mentioning

confidence: 99%

Hypergammaglobulinemia in an SIV-Infected Rhesus Macaque with a B-cell neoplasm with plasma cell differentiation

Kramer

Sanders-Beer

Spano

et al. 2011

Journal of Medical Primatology

View full text Add to dashboard Cite

show abstract

“…Based on a mean risk for carcinogenesis of 10% per Sv administered, the estimated number of radiationinduced cancers ranges between 0.5 and 40 per 1000 treated patients. When radiation is performed in elderly patients, the risk is reduced by a factor of approximately 3 [5][6][7][8][9].…”

Section: Radiation Therapy In Benign Diseases and Carcinogenesismentioning

confidence: 99%

Radiation therapy for the treatment of benign vascular, skeletal and soft tissue diseases

et al. 2008

View full text Add to dashboard Cite

The concept of radiation therapy for the treatment of benign diseases refers to the use of moderate to high-energy ionising radiation as part of the treatment of non-malignant, but not necessarily harmless, diseases. The usefulness of radiation therapy, based on the anti-inflammatory properties of ionising radiation, has long been known. Apart from the treatment of intracranial benign tumours, such as meningiomas and neurinomas, the prevention of cardiovascular restenosis or treatment of skeletal degenerative diseases are, without doubt, the main fields of action for radiation therapy in benign conditions. Nonetheless, many other non-cancer entities may benefit from ionising radiation therapy treatment. The purpose of this review is to highlight and update indications for treatment with radiation therapy in benign conditions, focusing on skeletal degenerative processes, vascular conditions and soft tissue diseases.

show abstract

The carcinogenic risk of high dose total body irradiation in non-human primates

Cited by 17 publications

References 21 publications

Tumorigenesis in High-Dose Total Body Irradiated Rhesus Monkeys—A Life Span Study

Tumorigenesis in High-Dose Total Body Irradiated Rhesus Monkeys—A Life Span Study

Hypergammaglobulinemia in an SIV-Infected Rhesus Macaque with a B-cell neoplasm with plasma cell differentiation

Radiation therapy for the treatment of benign vascular, skeletal and soft tissue diseases

Contact Info

Product

Resources

About